Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Aramchol

Generic Name: Aramchol

Drug Type: Small Molecule

Chemical Formula: C_₄₄H_₇₉NO_₅

CAS Number: 246529-22-6

Unique Ingredient Identifier: QE1Q24M65Y

Overview

Aramchol has been used in trials studying the treatment of HIV, Gallstones, Fatty Liver, Metabolic Syndrome, and Nonalcoholic Steatohepatitis, among others.

Background

Aramchol has been used in trials studying the treatment of HIV, Gallstones, Fatty Liver, Metabolic Syndrome, and Nonalcoholic Steatohepatitis, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets

Phase 1

Active, not recruiting

Posted: 2024/07/16

Sponsor:Galmed Pharmaceutica...

ID:NCT06502561

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

Phase 2

Not yet recruiting

Posted: 2023/10/23

Sponsor:Galmed Research and ...

ID:NCT06095986

An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol

Phase 1

Completed

Posted: 2023/05/24

Sponsor:Galmed Pharmaceutica...

ID:NCT05874336

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Phase 1

Completed

Posted: 2020/07/21

Sponsor:Galmed Research and ...

ID:NCT04480827

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

Phase 3

Suspended

Posted: 2019/09/26

Sponsor:Galmed Research and ...

ID:NCT04104321

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Galmed Pharmaceuticals Advances Novel Sublingual Semaglutide Formulation to Challenge Injectable GLP-1 Market

a month ago

Galmed Pharmaceuticals has signed a binding term sheet with Entomus for a novel sublingual semaglutide formulation using Self-Emulsifying Drug Delivery System technology that bypasses first-pass metabolism.

Galmed's Aramchol Shows Promising Results in Enhancing Regorafenib's Efficacy Against GI Cancers

a month ago

Aramchol, Galmed Pharmaceuticals' SCD1 inhibitor, significantly enhanced the anti-tumor effects of Bayer's Regorafenib in liver and colorectal cancer models through increased autophagy and death receptor signaling.

Galmed Discovers Novel Blood Biomarkers for Aramchol, Expanding Therapeutic Potential Beyond MASH

a month ago

Analysis of blood samples from Aramchol-treated patients in the Phase 3 ARMOR MASH study revealed a panel of 70 proteins that form a pharmacodynamic signature, indicating decreased markers of inflammation, oxidative stress, and atherosclerotic plaque formation.

Galmed Reports Promising Results for Aramchol Meglumine Formulation in Phase 1 Bioavailability Study

a month ago

Aramchol Meglumine, a new chemical entity with patent protection until 2035, demonstrated nearly double the bioavailability of the original Aramchol acid formulation in healthy volunteers.

Aramchol Shows Significant Anti-Fibrotic Effects in MASH Patients, Phase 3 Trial Results Published in Hepatology

8 months ago

Aramchol 300mg BID demonstrates a significant anti-fibrotic effect in patients with metabolic dysfunction-associated steatohepatitis (MASH), as confirmed by multiple objective measurements.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy